7th Obesity and NASH Summit

Eli Lilly's 'triple G' drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss, a new record for the obesity field has been set and the time to get ahead of the curve is now.

In parallel, we're witnessing history being made with the world's first approved NASH treatment potentially being right around the corner with Madrigal's THR β-selective agonist, marking this year a pivotal time for the metabolic field to forever elevate the approach towards drug development and overcome regulatory barriers.

Reuniting metabolic experts to enable the assessment of the competitive landscape, the 7th Obesity and NASH Drug Development Summit is your exclusive industry meeting to:

- Better understand the state of blood based, imaging and predictive biomarkers to meet primary endpoints and attain regulatory approval
- Explore GLP-1 RAs in a new light with FGF21, GIP, Amylin, glucagon receptors and more to lead to better therapeutic profile
- Ascertain a safety profile and successfully demonstrate efficacy in combination therapy to accurately assess multiple mechanisms of action

Join 160+ experts from Eli Lilly, Novo Nordisk, Madrigal, Akero, Gilead, Pfizer, AstraZeneca, Gilead, Inventiva, and many more to cultivate sustainable weight-loss drugs and navigate the route towards the first approval in NASH.

URLs:
Website: https://go.evvnt.com/1972456-0?pid=10018
Tickets: https://go.evvnt.com/1972456-2?pid=10018
Brochure: https://go.evvnt.com/1972456-3?pid=10018

Prices:
Drug Developer Conference + Workshop Day Ticket: USD 4946.00,
Drug Developer Conference Only: USD 2999.00,
Solution Provider Conference + Workshop Day: USD 6046.00,
Solution Provider Conference Only: USD 3799.00

Speakers: Erik Tillman, Associate Director, Translational Biology and Pharmacology, Akero Therapeutics, Feng Liu, Executive Director, Regor Therapeutics, Jen-Chieh (Jay) Chuang, Associate Director, Liver Diseases and Translational Biomarker Lead, Takeda, Jerry Colca, Chief Scientific Officer, Cirius Therapeutics, Jingye Zhou, Co-Founder and Chief Executive Officer, Eccogene, JoAnne Foody, Chief Medical Officer, Esperion, John Griffin, Postdoctoral Researcher, Pfizer, Kathleen Elias, Co-Founder and Vice President, Research and Translational Medicine, Seal Rock Therapeutics, Kavita Juneja, Senior Director, Head of Metabolic Therapeutic Development, Corcept Therepeutics, Kevin Hart, Scientific Director, Pfizer, Linh Hue Vong, Senior Director, Eli Lilly and Co., Marc Thibonnier, Founder and President, AptamiR Therapeutics, Marie O'Farrell, Senior Vice President, Research and Development, Sagimet Biosciences, Mark Hartman, Vice President, Medical, NASH/Obesity, Eli Lilly and Co., Mary Haas, Senior Manager, Cardiovascular Metabolic and Skeletal Disease Genetics, Regeneron Genetics Center, Michael P Cooreman, Chief Medical Officer, Inventiva, Michelle Long, International Medical Vice President, NASH, Novo Nordisk, ‪Miriam Kidron,‬‏ Chief Scientific Officer, Oramed Pharmaceuticals, Mourad Topors, Chief Scientific Officer, Repair Biotechnologies, Murielle Veniant-Ellison, Scientific Vice President, Amgen, Noah Davidsohn, Chief Scientific Officer, Rejuvenate Bio, Patrick Mayo, Senior Vice President, Clinical Pharmacology and Analytics, Hepion Pharmaceuticals, Rebecca Taub, Chief Medical Officer and President, Research and Development, Madrigal Pharmaceuticals, Rhianna Laker, Associate Director, AstraZeneca, Sara Toftegaard Hjuler, Department Manager, Obesity and NASH Pharmacology, Novo Nordisk, Sarah Vargas, Senior Scientist, Pfizer, Sharat Varma, Senior International Medical Director, Novo Nordisk, Shuqian Jing, Founder, Chairman and Chief Executive Officer, Gmax Biopharm, Stanley Watowich, Founder and Chief Executive Officer, Ridgeline Therapeutics, Sungjin Park, Chief Executive Officer, Onegene Biotechnology, Teo Uysal, President and Chief Executive Officer, ERX Pharmaceuticals, Tien Lee, Chief Executive Officer, Aardvark Therapeutics, Todd Hobbs, Chief Medical Officer, Hepion Pharmaceuticals, Vaidehi Joshi, Director, Discovery Biology, Viscient Bio, Wen-Wei Tsai, Director, Sagimet Biosciences, Wladislaw Malkov, Head of Clinical Bioinformatics, Data Sciences, Inflammation and Therapeutics Area, Gilead Sciences, Xinle Wu, Chief Scientific Officer and Head of Research, Sciwind Biosciences, Zhao (Joe) Wang, Regulatory Affairs Director, Late CVRM, AstraZeneca